Stryker Co. (NYSE:SYK) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Stryker Co. (NYSE:SYK) have earned an average recommendation of “Moderate Buy” from the twenty brokerages that are covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and seventeen have given a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $398.40.

SYK has been the subject of several recent analyst reports. Needham & Company LLC boosted their price target on shares of Stryker from $393.00 to $409.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Piper Sandler restated an “overweight” rating and issued a $420.00 target price (up previously from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. UBS Group lifted their price target on Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Evercore ISI raised their target price on shares of Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Finally, Royal Bank of Canada lifted their price objective on Stryker from $386.00 to $400.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th.

Insider Activity

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the transaction, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. This represents a 36.43 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP M Kathryn Fink sold 2,121 shares of Stryker stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $370.00, for a total value of $784,770.00. Following the sale, the vice president now directly owns 10,042 shares in the company, valued at approximately $3,715,540. The trade was a 17.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 66,781 shares of company stock worth $24,612,275 over the last ninety days. 5.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Stryker

Hedge funds and other institutional investors have recently modified their holdings of the stock. Dunhill Financial LLC lifted its position in shares of Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 37 shares during the last quarter. Centennial Bank AR lifted its holdings in shares of Stryker by 106.7% during the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after purchasing an additional 48 shares during the last quarter. Darwin Wealth Management LLC acquired a new position in shares of Stryker in the 3rd quarter valued at $36,000. HBW Advisory Services LLC purchased a new position in Stryker in the 3rd quarter worth about $42,000. Finally, Hara Capital LLC acquired a new stake in Stryker during the 3rd quarter worth about $42,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Up 0.3 %

Shares of SYK stock opened at $390.97 on Wednesday. The stock’s 50-day simple moving average is $369.58 and its 200-day simple moving average is $352.53. The firm has a market capitalization of $149.05 billion, a PE ratio of 41.90, a P/E/G ratio of 2.94 and a beta of 0.94. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. Stryker has a fifty-two week low of $285.79 and a fifty-two week high of $398.20.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The firm had revenue of $5.49 billion during the quarter, compared to analyst estimates of $5.37 billion. During the same quarter in the previous year, the business earned $2.46 EPS. Stryker’s revenue for the quarter was up 11.9% compared to the same quarter last year. Equities analysts expect that Stryker will post 12.06 earnings per share for the current year.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.